Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation
- 30 January 2007
- journal article
- Published by Wiley in Transplant Infectious Disease
- Vol. 9 (2) , 102-107
- https://doi.org/10.1111/j.1399-3062.2006.00183.x
Abstract
Antiviral compounds including ganciclovir, foscarnet, and cidofovir are routinely used in the treatment of cytomegalovirus (CMV) infection and disease; however, these agents have a poor oral bioavailability and have the inconvenience and expense of intravenous administration. To evaluate the safety and efficacy of oral valganciclovir (VGCV) for preemptive treatment of CMV reactivation in the setting of allogeneic hematopoietic stem cell transplantation (HSCT). We treated 15 patients receiving allogeneic HSCT from related (n=9) or unrelated (n=6) donors. In all patients, either the donor, host, or both were CMV Ig G positive pretransplant. Indication for therapy was preemptive treatment of CMV infection defined as one or two consecutive positive tests of pp65 antigenemia assay or CMV-polymerase chain reaction (PCR). VGCV was administered orally in a dosage of 900 mg b.i.d. for 2 weeks, followed by 450 mg b.i.d. for 2 additional weeks. Patients developed a positive CMV-PCR after a median of 52 days (range 37-427) post HSCT and a positive pp65 antigenemia after a median time of 74 days (range 37-427) post HSCT. Preemptive treatment with VGCV was started a median time of 56 days (range 37-429) after transplant. In all, 11 patients (73%) completed the 28 days of therapy with VGCV. All patients showed a complete clearance of the virus. The median time to achieve a negative CMV-PCR was 6 days (range 4-18). A relapse of CMV infection after VGCV preemptive therapy occurred in 6 patients (40%). No patient developed early or late CMV disease. Six patients (40%) presented hematological toxicity including neutropenia and/or thrombocytopenia that required drug discontinuation in 4 cases. VGCV administered as preemptive therapy for CMV infection in patients receiving an allogeneic HSCT showed promise for treating this frequent complication. Prospective randomized studies in this setting are mandatory to yield more definitive results.Keywords
This publication has 12 references indexed in Scilit:
- Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantationBlood, 2006
- A Prospective Assessment of Valganciclovir for the Treatment of Cytomegalovirus Infection and Disease in Transplant RecipientsThe Journal of Infectious Diseases, 2005
- Successful oral valganciclovir treatment of cytomegalovirus infection during Campath-1H therapyLeukemia, 2004
- Pharmacokinetics of Oral Valganciclovir and Intravenous Ganciclovir Administered to Prevent Cytomegalovirus Disease in an Adult Patient Receiving Small-Intestine TransplantationAntimicrobial Agents and Chemotherapy, 2004
- Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas–kidney, and pancreas transplantationClinical Transplantation, 2004
- Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant RecipientsAmerican Journal of Transplantation, 2004
- 238Oral (PO) Valganciclovir (VGC) for preemptive therapy of Cytomegalovirus (CMV) Antigenemia (AG) in hematopoietic stem cell transplant (HSCT) recipientsTransplantation and Cellular Therapy, 2003
- Long-Term Care after Hematopoietic-Cell Transplantation in AdultsNew England Journal of Medicine, 2002
- Pharmacokinetics of Valganciclovir and Ganciclovir Following Multiple Oral Dosages of Valganciclovir in HIV- and CMV-Seropositive VolunteersClinical Pharmacokinetics, 1999
- Oral Ganciclovir as Maintenance Treatment for Cytomegalovirus Retinitis in Patients with AIDSNew England Journal of Medicine, 1995